SCHEMBL12795339

SCHEMBL12795339

O=c1c2ccccc2sc2ccc(CCCCCl)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
MAPT P10636 5/20 0.48
ALDH1A1 P00352 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAOA P21397 5/20 0.44
MAOB P27338 5/20 0.44
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
HCRTR1 O43613 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11049828 0.86 KDM4E (0.51) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL11049850 0.84 KDM4E (0.50) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL52641 0.84 KDM4E (0.50) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL195467 0.84 KDM4E (0.50) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL29854556 0.84 KDM4E (0.50) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL11053472 0.84 KDM4E (0.53) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL11382474 0.83 GPR3 (0.47) KDM4EMAPTALDH1A1RAB9AL3MBTL1
SCHEMBL2307395 0.81 KDM4E (0.55) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL725252 0.81 KDM4E (0.55) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL10791944 0.79 RORA (0.46) KDM4EMAPTALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389769-B2 Polymerizable type II photoinitiators and curable compositions AGFA GRAPHICS NV (BE) 2013-03-05 US disclosed
US-8389769-B2 Polymerizable type II photoinitiators and curable compositions AGFA GRAPHICS NV (BE) 2013-03-05 US disclosed
US-20110063388-A1 POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS AGFA GRAPHICS NV (BE) 2011-03-17 US disclosed
US-20110063388-A1 POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS AGFA GRAPHICS NV (BE) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110063388-A1 POLYMERIZABLE TYPE II PHOTOINITIATORS AND CURABLE COMPOSITIONS CCNH, CRKL, ERH KDM4E 1945/4885MAPT 2196/4885ALDH1A1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.